Kathrin Bauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathrin Bauer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Andreas Engert
University Hospital of Cologne Cochrane Haematological Malignancies Group, Department I of Internal Medicine Kerpener Str. 62 Cologne Germany 50924
13 shared publicationsIna Monsef
University Hospital of Cologne
12 shared publicationsNicole Skoetz
University Hospital of Cologne
9 shared publicationsKarl-Anton Kreuzer
University Hospital of Cologne
6 shared publicationsFranz Hutzschenreuter
University Hospital of Cologne
5 shared publications- Nicole Skoetz
Institute of Public Health, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
4 shared publications
Latest Publications
- 14 November 2012
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2012 (11) , CD008079
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono- or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impact of these agents remains unclear, as there are hints for increased risk of severe infections. The objectives of this review are to provide an evidence-based answer regarding the clinical benefits and harms of monoclonal anti-CD20 antibodies (such as rituximab, ofatumumab, GA101) compared to no further therapy or to other anti-leukaemic therapies in patients with CLL, irrespective of disease status. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 12, 2011), MEDLINE (from January 1990 to 4 January 2012), and EMBASE (from 1990 to 20 March 2009) as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology, European Hematology Association and European Society of Medical Oncology) for randomised controlled trials (RCTs). We included RCTs examining monoclonal anti-CD20 antibodies compared to no further therapy or to anti-leukaemic therapy such as chemotherapy or monoclonal antibodies in patients with newly diagnosed or relapsed CLL. We used hazard ratios (HR) as effect measures for overall survival (OS), progression-free survival (PFS) and time to next treatment, and risk ratios (RR) for response rates, treatment-related mortality (TRM) and adverse events (AEs). Two review authors independently extracted data and assessed quality of trials. We screened a total of 1150 records. Seven RCTs involving 1763 patients were identified, but only five could be included in the two separate meta-analyses we performed. We judged the overall the quality of these trials as moderate to high. All trials were randomised and open-label studies. However, two trials were published as abstracts only, therefore we were unable to assess the potential risk of bias for these trials in detail. Three RCTs (N = 1421) assessed the efficacy of monoclonal anti-CD20 antibodies (i.e. rituximab) plus chemotherapy compared to chemotherapy alone. The meta-analyses showed a statistically significant OS (HR 0.78, 95% confidence interval (CI) 0.62 to 0.98, P = 0.03, the number needed to treat for an additional beneficial effect (NNTB) was 12) and PFS (HR 0.64, 95% CI 0.55 to 0.74, P < 0.00001) advantage for patients receiving rituximab. In the rituximab-arm occurred more AEs, World Health Organization (WHO) grade 3 or 4 (3 trials, N = 1398, RR 1.15, 95% CI 1.08 to 1.23, P < 0.0001; the number needed to harm for an additional harmful outcome (NNTH) was 9), but that did not lead to a statistically significant difference regarding TRM (3 trials, N = 1415, RR 1.19, 95% CI 0.70 to 2.01, P = 0.52). Two trials (N = 177) evaluated rituximab versus alemtuzumab. Neither study reported OS or PFS. There was no statistically significant difference between arms regarding complete response rate (CRR) (RR 1.21, 95% CI 0.94 to 1.58, P = 0.14) or TRM (RR 0.31, 95% CI 0.06 to 1.51, P = 0.15). However, the CLL2007FMP trial was stopped early owing to an increase in mortality in the alemtuzumab arm. More serious AEs occurred in this arm (43% with alemtuzumab versus 22% with rituximab; P = 0.006). Two trials assessed different dosages or time schedules of monoclonal anti-CD20 antibodies. One trial (N = 104) evaluated two different rituximab schedules (concurrent arm: fludarabine plus rituximab (Flu-R) plus rituximab consolidation versus sequential arm: fludarabine alone plus rituximab consolidation). The comparison of the concurrent versus sequential regimen of rituximab showed a statistically significant difference of the CRR with 33% in the concurrent-arm and 15% in the sequential-arm (P = 0.04), that did not lead to statistically significant differences regarding OS (HR 1.14, 95% CI 0.20 to 6.65, P = 0.30) or PFS (HR 0.96, 95% CI 0.43 to 2.15, P = 0.11). Furthermore results showed no differences in occurring AEs, except for neutropenia, which was more often observed in patients of the concurrent arm. The other trial (N = 61) investigated two different dosages (500 mg and 1000 mg) of ofatumumab in addition to FluC. The arm investigating ofatumumab did not assess OS and a median PFS had not been reached owing to the short median follow-up of eight months. It showed no statistically significant differences between arms regarding CRR (32% in the FCO500 arm versus 50% in the FCO1000 arm; P = 0.10) or AEs (anaemia, neutropenia, thrombocytopenia). This meta-analysis showed that patients receiving chemotherapy plus rituximab benefit in terms of OS as well as PFS compared to those with chemotherapy alone. Therefore, it supports the recommendation of rituximab in combination with FluC as an option for the first-line treatment as well as for the people with relapsed or refractory CLL. The available evidence regarding the other assessed comparisons was not sufficient to deduct final conclusions. Rituximab, ofatumumab et autres anticorps monoclonaux anti-CD20 pour le traitement de la leucémie lymphoïde chronique La leucémie lymphoïde chronique (LLC) représente 25 % de toutes les leucémies et constitue la malignité lymphoïde la plus fréquente dans les pays occidentaux. Les traitements standard sont notamment les mono- et poly-chimiothérapies, généralement combinées à des anticorps monoclonaux tels que le rituximab ou l'alemtuzumab. Toutefois, l'impact de ces agents reste incertain, étant donnés les indices d'un risque accru d'infections graves. Les objectifs de cette revue sont de fournir une réponse s'appuyant sur des bases factuelles concernant les bénéfices cliniques et les préjudices liés aux anticorps monoclonaux anti-CD20 (tels que le rituximab, l'ofatumumab et le GA101) par...
- 14 November 2012
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2012 (11) , CD008079
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono- or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impact of these agents remains unclear, as there are hints for increased risk of severe infections. The objectives of this review are to provide an evidence-based answer regarding the clinical benefits and harms of monoclonal anti-CD20 antibodies (such as rituximab, ofatumumab, GA101) compared to no further therapy or to other anti-leukaemic therapies in patients with CLL, irrespective of disease status. We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 12, 2011), MEDLINE (from January 1990 to 4 January 2012), and EMBASE (from 1990 to 20 March 2009) as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology, European Hematology Association and European Society of Medical Oncology) for randomised controlled trials (RCTs). We included RCTs examining monoclonal anti-CD20 antibodies compared to no further therapy or to anti-leukaemic therapy such as chemotherapy or monoclonal antibodies in patients with newly diagnosed or relapsed CLL. We used hazard ratios (HR) as effect measures for overall survival (OS), progression-free survival (PFS) and time to next treatment, and risk ratios (RR) for response rates, treatment-related mortality (TRM) and adverse events (AEs). Two review authors independently extracted data and assessed quality of trials. We screened a total of 1150 records. Seven RCTs involving 1763 patients were identified, but only five could be included in the two separate meta-analyses we performed. We judged the overall the quality of these trials as moderate to high. All trials were randomised and open-label studies. However, two trials were published as abstracts only, therefore we were unable to assess the potential risk of bias for these trials in detail. Three RCTs (N = 1421) assessed the efficacy of monoclonal anti-CD20 antibodies (i.e. rituximab) plus chemotherapy compared to chemotherapy alone. The meta-analyses showed a statistically significant OS (HR 0.78, 95% confidence interval (CI) 0.62 to 0.98, P = 0.03, the number needed to treat for an additional beneficial effect (NNTB) was 12) and PFS (HR 0.64, 95% CI 0.55 to 0.74, P < 0.00001) advantage for patients receiving rituximab. In the rituximab-arm occurred more AEs, World Health Organization (WHO) grade 3 or 4 (3 trials, N = 1398, RR 1.15, 95% CI 1.08 to 1.23, P < 0.0001; the number needed to harm for an additional harmful outcome (NNTH) was 9), but that did not lead to a statistically significant difference regarding TRM (3 trials, N = 1415, RR 1.19, 95% CI 0.70 to 2.01, P = 0.52). Two trials (N = 177) evaluated rituximab versus alemtuzumab. Neither study reported OS or PFS. There was no statistically significant difference between arms regarding complete response rate (CRR) (RR 1.21, 95% CI 0.94 to 1.58, P = 0.14) or TRM (RR 0.31, 95% CI 0.06 to 1.51, P = 0.15). However, the CLL2007FMP trial was stopped early owing to an increase in mortality in the alemtuzumab arm. More serious AEs occurred in this arm (43% with alemtuzumab versus 22% with rituximab; P = 0.006). Two trials assessed different dosages or time schedules of monoclonal anti-CD20 antibodies. One trial (N = 104) evaluated two different rituximab schedules (concurrent arm: fludarabine plus rituximab (Flu-R) plus rituximab consolidation versus sequential arm: fludarabine alone plus rituximab consolidation). The comparison of the concurrent versus sequential regimen of rituximab showed a statistically significant difference of the CRR with 33% in the concurrent-arm and 15% in the sequential-arm (P = 0.04), that did not lead to statistically significant differences regarding OS (HR 1.14, 95% CI 0.20 to 6.65, P = 0.30) or PFS (HR 0.96, 95% CI 0.43 to 2.15, P = 0.11). Furthermore results showed no differences in occurring AEs, except for neutropenia, which was more often observed in patients of the concurrent arm. The other trial (N = 61) investigated two different dosages (500 mg and 1000 mg) of ofatumumab in addition to FluC. The arm investigating ofatumumab did not assess OS and a median PFS had not been reached owing to the short median follow-up of eight months. It showed no statistically significant differences between arms regarding CRR (32% in the FCO500 arm versus 50% in the FCO1000 arm; P = 0.10) or AEs (anaemia, neutropenia, thrombocytopenia). This meta-analysis showed that patients receiving chemotherapy plus rituximab benefit in terms of OS as well as PFS compared to those with chemotherapy alone. Therefore, it supports the recommendation of rituximab in combination with FluC as an option for the first-line treatment as well as for the people with relapsed or refractory CLL. The available evidence regarding the other assessed comparisons was not sufficient to deduct final conclusions. Rituximab, ofatumumab et autres anticorps monoclonaux anti-CD20 pour le traitement de la leucémie lymphoïde chronique La leucémie lymphoïde chronique (LLC) représente 25 % de toutes les leucémies et constitue la malignité lymphoïde la plus fréquente dans les pays occidentaux. Les traitements standard sont notamment les mono- et poly-chimiothérapies, généralement combinées à des anticorps monoclonaux tels que le rituximab ou l'alemtuzumab. Toutefois, l'impact de ces agents reste incertain, étant donnés les indices d'un risque accru d'infections graves. Les objectifs de cette revue sont de fournir une réponse s'appuyant sur des bases factuelles concernant les bénéfices cliniques et les préjudices liés aux anticorps monoclonaux anti-CD20 (tels que le rituximab, l'ofatumumab et le GA101) par...
- 16 May 2012
- Published by Wiley
- Vol. 9 (5)
Thrombopoietin mimetics for patients with myelodysplastic syndromes
- 16 May 2012
- Published by Wiley
- Vol. 9 (5)
Thrombopoietin mimetics for patients with myelodysplastic syndromes
- 7 December 2011
- Published by Wiley
- No. 12
Low dose cytarabine monotherapy for myelodysplastic syndromes
- 7 December 2011
- Published by Wiley
- No. 12
Low dose cytarabine monotherapy for myelodysplastic syndromes
- 7 December 2011
- Published by Wiley
- No. 12
Low dose cytarabine monotherapy for acute myeloid leukaemia
- 7 December 2011
- Published by Wiley
- No. 12
Hypomethylating agents for adult patients with acute myeloid leukaemia
- 7 December 2011
- Published by Wiley
- No. 12
Hypomethylating agents for adult patients with acute myeloid leukaemia
- 5 October 2011
- Published by Wiley
- No. 10
Intravenous immunoglobulins for the treatment of infections in patients with haematological cancers
- 5 October 2011
- Published by Wiley
- No. 10
Intravenous immunoglobulins for the treatment of infections in patients with haematological cancers
- 5 October 2011
- Published by Wiley
- No. 10
Hypomethylating agents for patients with myelodysplastic syndrome
- 5 October 2011
- Published by Wiley
- No. 10
Hypomethylating agents for patients with myelodysplastic syndrome
- 7 September 2011
- Published by Wiley
- No. 9
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
- 7 September 2011
- Published by Wiley
- No. 9
Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
- Open Access
- 20 July 2011
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (17) , E1-E19
Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma
- 20 July 2011
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (17) , E1-E19
Open AccessThirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma